CytoSorbents Hits Cash Flow Breakeven in Third Quarter 2026
CytoSorbents reports Q3 2026 financial results, reaching operating cash flow breakeven as the company advances its blood purification pipeline.
CytoSorbents Corporation (NASDAQ: CTSO) reported its third-quarter 2026 financial results on Wednesday, announcing that the Princeton, N.J.-based medical device company achieved operating cash flow breakeven — a milestone the company characterized as the first of four distinct value drivers in its strategic roadmap.
The company, which specializes in blood purification technologies aimed at treating life-threatening conditions in intensive care units and during cardiac surgery, framed the breakeven threshold as a signal of improving financial discipline alongside its ongoing regulatory and commercial efforts.
Read more USDA Forecasts Less Beef, More Chicken Production in 2027 →
Along with the financial update, CytoSorbents provided a broader business and regulatory update, suggesting pipeline and compliance milestones remain active priorities for the remainder of the fiscal year. The simultaneous disclosure of financial and operational progress reflects a pattern among smaller-cap medical device firms seeking to reassure investors of near-term stability while telegraphing longer-term growth catalysts.
CytoSorbents trades on the Nasdaq under the ticker symbol CTSO. Achieving cash flow breakeven is generally viewed by analysts as a credibility marker for pre-profitability companies, reducing the urgency for near-term dilutive financing while the company pursues regulatory approvals and market expansion.
Continue reading at Earnings for the full financial tables and regulatory details.